OncLive® On Air

In today’s episode, we spoke with Colin Vale, MD. Dr Vale is an assistant professor in the Department of Hematology and Medical Oncology at the Emory University School of Medicine in Atlanta, Georgia.

In our exclusive interview, Dr Vale discussed data from a phase 2 trial (NCT03263572) evaluating blinatumomab (Blincyto) plus ponatinib (Iclusig) in patients with Philadelphia chromosome–positive B-cell acute lymphoblastic leukemia. In addition to underscoring the findings and their clinical significance, Vale expanded on how the combination can improve patient quality of life by helping patients avoid procedures like allogeneic stem cell transplant.

Highlights from the PER® CME activity "Medical Crossfire®: Menin Inhibitors in AML—Dissecting the Data to Define the Role" — this podcast is not certified for credit. To participate in the full accredited activity and earn CME credit, use the link below.

In this podcast, experts Naval Daver, MD; Courtney DiNardo, MD; and Eunice Wang, MD; discuss the rationale for treatment with menin inhibitors—and the data showing their efficacy and safety—in acute myeloid leukemia (AML).

Earn CME credit by completing the full accredited activity (available through March 17, 2027):
https://www.gotoper.com/courses/medical-crossfire-menin-inhibitors-in-amldissecting-the-data-to-define-the-role-3ng9

This podcast, including the narration, was developed by PER® (Physicians’ Education Resource®, LLC) editorial staff from the full online CME activity developed with these faculty. The narration was voiced by a PER staff member or by an AI tool. The podcast contains no product advertising. The full activity is supported by educational grants from Janssen Scientific Affairs, LLC, Kura Oncology, and Syndax Pharmaceuticals, Inc.

This content is for educational purposes only and is not a substitute for the independent clinical judgment of a health care professional. Faculty may discuss investigational or off-label uses; consult prescribing information for any products discussed.

In this episode, Gregory J. Tiesi, MD, FACS, FSSO, hosted a discussion about the growing role for transarterial microperfusion (TAMP) as a regional therapy strategy for patients with locally advanced pancreatic ductal adenocarcinoma (PDAC). 

Dr Tiesi is the medical director of Hepatobiliary Surgery at the Hackensack Meridian Jersey Shore University Medical Center in Neptune, New Jersey. He was joined by: 

PDAC is a disease in which dense desmoplastic stroma and poor tumor vascularization often limit the effectiveness of standard systemic chemotherapy. Drs Tiesi, Scholer, and Pletcher explained that standard regimens, such as FOLFIRINOX or gemcitabine-based combinations, frequently fail to achieve adequate intratumoral drug concentrations because of these biologic barriers. TAMP aims to overcome this limitation by isolating a segment of an arterial vessel and pressure-mediated transvascular delivery, which would allow for higher local drug concentrations and reduce systemic exposure and toxicity. 

The experts noted that TAMP is currently being explored primarily in patients with locally advanced, unresectable pancreatic cancer without distant metastases, particularly those who have exhausted systemic treatment options but maintain localized disease. Early clinical studies, including the phase 1/2 RR1 trial (NCT02237157) and the observational RR2 dose-escalation study (NCT02591082), demonstrated that the procedure is technically feasible, repeatable, and associated with lower systemic toxicity compared with conventional chemotherapy. A pooled analysis of these studies suggested encouraging survival outcomes, particularly in patients who received prior chemoradiation, potentially because radiation modifies the tumor microenvironment and improves drug penetration. 

Lastly, Tiesi, Scholer and Pletcher reviewed the ongoing phase 3 TIGeR-PaC trial (NCT03257033), which is evaluating TAMP as a consolidation strategy after induction chemotherapy and radiation. Preliminary data suggest improved survival and substantially fewer serious adverse effects with TAMP vs continued systemic therapy alone. Although the experts cautioned that the approach remains investigational, they agreed that TAMP may provide meaningful local disease control and potentially expand treatment options and preserve quality of life for patients with this aggressive malignancy. 

Highlights from the PER® CME activity "Show Me the Data™—Closing Clinical Gaps in Gastric and Esophageal Cancer: Advancing Targeted Treatment Strategies Across the Care Continuum" — this podcast is not certified for credit. To participate in the full accredited activity and earn CME credit, use the link below.

In this podcast, experts Manish A. Shah, MD, FASCO; Syma Iqbal, MD; and Haeseong Park, MD, MPH; discuss novel combinations of targeted therapy, immunotherapy, and chemotherapy to treat resectable and unresectable gastroesophageal adenocarcinomas.

Earn CME credit by completing the full accredited activity (available through March 13, 2027):
https://www.gotoper.com/smtd26gea-activity

This podcast, including the narration, was developed by PER® (Physicians’ Education Resource®, LLC) editorial staff from the full online CME activity developed with these faculty. The narration was voiced by a PER staff member or by an AI tool. The podcast contains no product advertising. The full activity is supported by an educational grant from AstraZeneca Pharmaceuticals.

This content is for educational purposes only and is not a substitute for the independent clinical judgment of a health care professional. Faculty may discuss investigational or off-label uses; consult prescribing information for any products discussed.

Welcome to OncLive On Air®! I’m your host today, Kyle Doherty.

OncLive On Air is a podcast from OncLive®, which provides oncology professionals with the resources and information they need to provide the best patient care. In both digital and print formats, OncLive covers every angle of oncology practice, from new technology to treatment advances to important regulatory decisions.

In today’s episode, we spoke with Sonali Smith, MD. Dr Smith holds the Elwood V. Jensen Professorship of Medicine and is the chief of the Section of Hematology/Oncology at UChicago Medicine. 

In our exclusive interview, Dr Smith discussed CAR-T cell therapies moving into solid tumors, the role of clinical trials in hematologic oncology, and the rising incidence of certain cancers in young adults.

_____

That’s all we have for today! Thank you for listening to this episode of OncLive On Air. Check back throughout the week for exclusive interviews with leading experts in the oncology field.

For more updates in oncology, be sure to visit www.OncLive.com and sign up for our e-newsletters.

OncLive is also on social media. On X and BlueSky, follow us at @OncLive. On Facebook, like us at OncLive, and follow our OncLive page on LinkedIn.

If you liked today’s episode of OncLive On Air, please consider subscribing to our podcast on Apple Podcasts, Spotify, and many of your other favorite podcast platforms,* so you get a notification every time a new episode is posted. While you are there, please take a moment to rate us!

Thanks again for listening to OncLive On Air.

*OncLive On Air is available on: Apple Podcasts, Spotify, CastBox, Podcast Addict, Podchaser, RadioPublic, and TuneIn.

This content is a production of OncLive; this OncLive On Air podcast episode is supported by funding, however, content is produced and independently developed by OncLive.

Highlights from the PER® CME activity "Tumor Board: Translating HER2 and TROP2 Innovations to Transform NSCLC Care" — this podcast is not certified for credit. To participate in the full accredited activity and earn CME credit, use the link below.

In this podcast, experts Jacob Sands, MD; Marina Chiara Garassino, MD; and Eric Singhi, MD; use realistic cases to explore key decision points in applying HER2- and TROP2-targeted therapies across the non–small cell lung cancer (NSCLC) continuum, including patient selection, sequencing, and toxicity management.

Earn CME credit by completing the full accredited activity (available through March 11, 2027):
https://www.gotoper.com/tb26-her2-trop2-nsclc-activity

This podcast, including the narration, was developed by PER® (Physicians’ Education Resource®, LLC) editorial staff from the full online CME activity developed with these faculty. The narration was voiced by a PER staff member or by an AI tool. The podcast contains no product advertising. The full activity is supported by educational grants from AstraZeneca Pharmaceuticals, Inc; and Daiichi Sankyo, Inc.

This content is for educational purposes only and is not a substitute for the independent clinical judgment of a health care professional. Faculty may discuss investigational or off-label uses; consult prescribing information for any products discussed.

Highlights from the PER® CME activity "Show Me the Data™: Post-TKI Sequencing in EGFR-Mutated NSCLC—Optimizing Current Strategies and Preparing for New Treatment Modalities" — this podcast is not certified for credit. To participate in the full accredited activity and earn CME credit, use the link below.

In this podcast, experts Christine M. Lovly, MD, PhD, FASCO; Lyudmila Bazhenova, MD; Hossein Borghaei, DO, MS; and Xiuning Le, MD, PhD, discuss how to sequence systemic therapy based on the molecular profile of non–small cell lung cancer that has progressed on a first-line EGFR-directed tyrosine kinase inhibitor, including discussion on the use of bispecific antibodies in this setting.

Earn CME credit by completing the full accredited activity (available through March 10, 2027):
https://www.gotoper.com/smtd26egfrnsclc-activity

This podcast, including the narration, was developed by PER® (Physicians’ Education Resource®, LLC) editorial staff from the full online CME activity developed with these faculty. The narration was voiced by a PER staff member or by an AI tool. The podcast contains no product advertising. The full activity is supported by an educational grant from Summit Therapeutics, Inc.

This content is for educational purposes only and is not a substitute for the independent clinical judgment of a health care professional. Faculty may discuss investigational or off-label uses; consult prescribing information for any products discussed.

In today’s episode, we sat down with Kelly E. McCann, MD, PhD, and Sara Nunnery, MD, MSCI, as they shared their stories and perspectives as leading women in oncology in honor of International Women's Day, which is observed annually on March 8. Dr McCann is a breast medical oncologist in the University of California system. Dr Nunnery is a breast medical oncologist with Tennessee Oncology in Nashville.

Forming the backdrop of our exclusive discussion were insights shared during the 2026 OncLive Women in Oncology event, which took place on March 5, 2026, to kick off the 43rd Annual Miami Breast Cancer Conference. In our exclusive interview, Drs McCann and Nunnery used the Women in Oncology discussion as the basis for relaying their own experiences, observations, and advice regarding setting boundaries, striving for work-life harmony, advocating for oneself, and more.

Highlights from the PER® CME activity "Medical Crossfire®: Breakthroughs in Non–Muscle-Invasive Bladder Cancer: Advancing Patient Care Through Innovation in Treatment" — this podcast is not certified for credit. To participate in the full accredited activity and earn CME credit, use the link below.

In this podcast, experts Ashish M. Kamat, MD, MBBS, Katie S. Murray, DO, MS, and Thomas Powles, MD, MBBS, MRCP, discuss the classification of BCG responsiveness and intravesical and systemic therapies for non-muscle invasive bladder cancer.

Earn CME credit by completing the full accredited activity (available through March 6, 2027):
https://www.gotoper.com/courses/medical-crossfire-breakthroughs-in-nonmuscle-invasive-bladder-cancer-advancing-patient-care-through-innovation-in-treatment-36p7">

This podcast, including the narration, was developed by PER® (Physicians’ Education Resource®, LLC) editorial staff from the full online CME activity developed with these faculty. The narration was voiced by a PER staff member or by an AI tool. The podcast contains no product advertising. The full activity is supported by an educational grant from Ferring Pharmaceuticals.

This content is for educational purposes only and is not a substitute for the independent clinical judgment of a health care professional. Faculty may discuss investigational or off-label uses; consult prescribing information for any products discussed.